Insight Molecular Diagnostics Inc. cash flow to debt ratio of -634.37% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Insight Molecular Diagnostics Inc.'s free cash flow has decreased 19.50% from $-21.23M last year to $-25.37M, signaling decreasing performance

Insight Molecular Diagnostics Inc.'s debt to equity ratio is -0.12, signaling that the company spent its equity and risk bankruptcy.

Insight Molecular Diagnostics Inc.'s debt to equity ratio is -0.12, signaling that the company spent its equity and risk bankruptcy.

Insight Molecular Diagnostics Inc. has a net cash position, so leverage is healthy.

Insight Molecular Diagnostics Inc.'s interest coverage ratio is -436.03, which means that the company struggles to meet interest obligations, signaling financial risk.

Insight Molecular Diagnostics Inc.'s profit margin has increased (-8.35%) in the last year from -3.23K% to -2.96K%, signaling increasing performance

Insight Molecular Diagnostics Inc.'s short-term assets of $15.31M exceed its short-term liabilities of $12.07M

Insight Molecular Diagnostics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Insight Molecular Diagnostics Inc.'s return on equity of 271.76%, is higher than 15.00%, indicating good performance

Insight Molecular Diagnostics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Insight Molecular Diagnostics Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Insight Molecular Diagnostics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Insight Molecular Diagnostics Inc. has negative free cash flow, indicating cash burn

Insight Molecular Diagnostics Inc.'s yearly earnings has increased -17.21% since last year from $-60.66M to $-50.22M, signaling increasing performance

Insight Molecular Diagnostics Inc.'s yearly revenue has increased 115.58% since last year from $1.88M to $4.05M, signaling increasing performance

ROIC -204.78% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Insight Molecular Diagnostics Inc.'s 3-year revenue CAGR of 61.76% is positive, indicating growing revenue over the past 3 years

Insight Molecular Diagnostics Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Insight Molecular Diagnostics Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Insight Molecular Diagnostics Inc. has insufficient data to evaluate this check.

Insight Molecular Diagnostics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Insight Molecular Diagnostics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Insight Molecular Diagnostics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Insight Molecular Diagnostics Inc. is overvalued relative to its fair value price of -48.38 based on Earnings Fair Value model

Insight Molecular Diagnostics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Insight Molecular Diagnostics Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Insight Molecular Diagnostics Inc. has a price-to-sales ratio of 105.07x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue